<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Merck Ltd. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=10619></link><description><![CDATA[Merck Ltd. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Mon, 18 May 2026 17:29:16 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><language>ko-KR</language><item><title><![CDATA[Cosmetic pigments from Merck receive ECOCERT Certificate]]></title><link>https://www.newswire.co.kr/newsRead.php?no=355455</link><description><![CDATA[Seoul--(뉴스와이어)--Cosmetic pigments and functional fillers of Merck KGaA sold under the brand names Biron®, Colorona® and Timiron® have been certified in compliance with the ECOCERT standard.  ECOCERT is currently the most important internationally recognized certificate for natural cosmetics. To receive this certificate, cosmetic ingredients must meet the very s...]]></description><pubDate>Tue, 26 Aug 2008 08:51:28 +0900</pubDate></item><item><title><![CDATA[Merck Serono Receives European Approval for broader usage of Erbitux in Metastatic Colorectal Cancer including 1st-Line Treatment]]></title><link>https://www.newswire.co.kr/newsRead.php?no=350160</link><description><![CDATA[Darmstadt--(뉴스와이어)--Merck KGaA announced today that it has been granted approval by the European Commission for Erbitux (cetuximab), to update its license for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type mCRC (metastatic colorectal cancer) in combination with chemotherapy, and as a single agent in patients who ha...]]></description><pubDate>Fri, 25 Jul 2008 09:29:59 +0900</pubDate></item><item><title><![CDATA[Erbitux receives KFDA approval with prolonged survival by 20 months in patients with head and neck cancer]]></title><link>https://www.newswire.co.kr/newsRead.php?no=347520</link><description><![CDATA[Seoul--(뉴스와이어)--Merck Ltd. Korea, the Korean subsidiary of Merck KGaA of Germany, announced that it has been granted approval by KFDA (Korea Food &amp; Drug Administration) for the use of Erbitux in combination with radiotherapy in patients with locally advanced head and neck cancer.  Erbitux is the first targeted therapy for head and neck cancer and has been l...]]></description><pubDate>Mon, 14 Jul 2008 09:38:40 +0900</pubDate></item><item><title><![CDATA[Merck Serono: Erbitux? Phase III Clinical Study in Gastric Cancer Started]]></title><link>https://www.newswire.co.kr/newsRead.php?no=347180</link><description><![CDATA[Seoul--(뉴스와이어)--Merck Serono, a division of Merck KGaA, announced today that the first patient has been enrolled into its pivotal Phase III gastric cancer clinical study, EXPAND (Erbitux in combination with Xeloda and cisplatin in advanced esophago-gastric cancer). The study will assess the clinical benefit of the targeted cancer therapy Erbitux(cetuximab) in c...]]></description><pubDate>Fri, 11 Jul 2008 09:03:49 +0900</pubDate></item><item><title><![CDATA[Merck Breaks Ground on New Advanced Technology Center]]></title><link>https://www.newswire.co.kr/newsRead.php?no=346777</link><description><![CDATA[Seoul--(뉴스와이어)--Merck in Korea, a Korean subsidiary of Merck KGaA of Darmstadt, Germany, held a groundbreaking ceremony today for its new Advanced Technology Center (ATC) in Poseung, Korea.  “Merck will continue to support their customers, allowing them to achieve business success through our advanced technologies and close relationships,” said Dr. Frank Stange...]]></description><pubDate>Wed, 09 Jul 2008 15:06:17 +0900</pubDate></item><item><title><![CDATA[“Meet Merck in Our Daily Life”...German World 2008]]></title><link>https://www.newswire.co.kr/newsRead.php?no=337608</link><description><![CDATA[Seoul--(뉴스와이어)--Merck Korea, a Korean subsidiary of Merck KGaA Germany, will join German World 2008, where it will demonstrate how to meet Merck in daily life.  Merck is the oldest pharmaceutical and chemical company in the world and market leader for  liquid crystals. Merck Korea Ltd. was founded in 1989 and established Merck Advanced Technologies Ltd. (MAT) i...]]></description><pubDate>Thu, 29 May 2008 09:13:40 +0900</pubDate></item><item><title><![CDATA[Merck Confirms Its Commitment to Korea]]></title><link>https://www.newswire.co.kr/newsRead.php?no=333781</link><description><![CDATA[Seoul--(뉴스와이어)--Merck in Korea, a Korean subsidiary of Merck KGaA of Darmstadt, Germany, announced today that an executive board member of the parent company, Dr. Bernd Reckmann, is visiting Korea in his new capacity as the first chairman of the German Korean Business Association.  Dr. Reckmann, who is responsible for Merck’s global Chemicals business sector, p...]]></description><pubDate>Fri, 09 May 2008 14:36:35 +0900</pubDate></item><item><title><![CDATA[RonaCare? Ectoin - a key cosmetic ingredient]]></title><link>https://www.newswire.co.kr/newsRead.php?no=328037</link><description><![CDATA[Seoul--(뉴스와이어)--RonaCare Ectoin, an ultrapure natural substance from Merck KGaA, is becoming increasingly important in the cosmetics industry. Cosmetic companies that sell their products in pharmacies and health stores as well as exclusive manufacturers are opting for the innovative ingredient that protects the skin’s immune system from stress and effectively f...]]></description><pubDate>Mon, 14 Apr 2008 09:07:50 +0900</pubDate></item><item><title><![CDATA[Merck to Invest 14 Billion KRW in Korean Advanced Technology Center]]></title><link>https://www.newswire.co.kr/newsRead.php?no=316777</link><description><![CDATA[Seoul--(뉴스와이어)--Merck KGaA of Darmstadt, Germany, the world’s leading supplier of liquid crystals, announced to today that it will invest 14 Billion Korean Won (EUR 11 million) to establish an Advanced Technology Center (‘ATC’) in Korea on January XX, 2008.  The investment will enhance Merck’s R&amp;D and manufacturing capacities, thus strengthening its positio...]]></description><pubDate>Thu, 14 Feb 2008 10:11:59 +0900</pubDate></item></channel></rss>